Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$2.02 - $3.02 $128,270 - $191,770
63,500 New
63,500 $170,000
Q3 2023

Nov 14, 2023

SELL
$0.96 - $1.79 $107,641 - $200,707
-112,127 Reduced 99.94%
65 $0
Q2 2023

Aug 14, 2023

SELL
$1.2 - $1.76 $132,993 - $195,057
-110,828 Reduced 49.69%
112,192 $155,000
Q1 2023

May 15, 2023

SELL
$1.46 - $7.3 $995,511 - $4.98 Million
-681,857 Reduced 75.35%
223,020 $354,000
Q4 2022

Sep 21, 2023

BUY
$5.09 - $8.5 $4.03 Million - $6.74 Million
792,685 Added 706.54%
904,877 $5.64 Million
Q4 2022

Feb 14, 2023

BUY
$5.09 - $8.5 $4.61 Million - $7.69 Million
904,877 New
904,877 $5.64 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $156M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Jefferies Financial Group Inc. Portfolio

Follow Jefferies Financial Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Financial Group Inc. with notifications on news.